You are here

  • Home
  • Archive
  • Volume 93, Issue 2
  • Intracameral bevacizumab effectively reduces aqueous vascular endothelial growth factor concentrations in neovascular glaucoma

Article Text

Article menu
Download PDFPDF
Letter
Intracameral bevacizumab effectively reduces aqueous vascular endothelial growth factor concentrations in neovascular glaucoma
  1. S Grover,
  2. S Gupta,
  3. R Sharma,
  4. V S Brar,
  5. K V Chalam
  1. Department of Ophthalmology, University of Florida, Health Science Center/Jacksonville, Jacksonville, Florida, USA
  1. Dr S Grover, Department of Ophthalmology, University of Florida, 580 West 8th Street, Tower 2, 3rd Floor, Jacksonville, FL 32209, USA; sgrover{at}jax.ufl.edu

https://doi.org/10.1136/bjo.2008.145714

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Vascular endothelial growth factor (VEGF) concentrations in both the aqueous and vitreous are raised in ocular ischaemia secondary to exudative age-related macular degeneration, diabetes mellitus and other retinal vascular diseases.1 2 Retinal ischaemia upregulates VEGF production, resulting in neovascularisation of the retina and the iris (NVI). VEGF is significantly increased in neovascular glaucoma (NVG).3

    In the following case series, we show increased aqueous VEGF concentrations in two patients with NVI, which significantly declined, with concurrent resolution of NVI, after off-label intracameral injections of bevacizumab.

    Materials and methods

    Two patients with NVI secondary to proliferative diabetic retinopathy were included in the study. After informed consent had been obtained, according to a protocol approved by the University of Florida Institutional Review Board, aqueous was collected before the injection of 0.05 ml intracameral bevacizumab (25 mg/ml) and …

    View Full Text

    Footnotes

    • Funding: Foundation Fighting Blindness, Owings Mills, Maryland, USA; Dean’s Grant Support, University of Florida, Jacksonville, Florida, USA. Study sponsors did not participate in the study design, the collection, analysis and interpretation of data, the writing of the report, or the decision to submit the paper for publication.

    • Competing interests: None.

    • Ethics approval: From the local University of Florida IRB.

    • Patient consent: Obtained.